Seastar Medical Holding CORP

SeaStar Medical Holding Corporation has entered into retention bonus agreements with executives Eric Schlorff and Kevin Chung, including cash payments and potential restricted stock units, to incentivize continued employment.

SeaStar Medical Holding Corporation held its annual stockholder meeting, approving an amendment to increase shares available under its 2022 Omnibus Incentive Plan.

SeaStar Medical announced a 69% year-over-year increase in first-quarter revenue driven by QUELIMMUNE sales and provided updates on its pivotal trials for adult AKI treatment.

SeaStar Medical Holding Corporation announced the dismissal with prejudice of a putative class action lawsuit alleging material misstatements and omissions.

SeaStar Medical announced significant revenue growth and clinical trial advancements for its life-saving therapies in its Q4 and full-year 2025 financial results.

SeaStar Medical Holding Corporation announced it has regained compliance with Nasdaq's minimum bid price requirement, effective January 20, 2026.

SeaStar Medical Holding Corporation reported increased revenue in Q1 2026 driven by QUELIMMUNE adoption, though net losses persisted.

SeaStar Medical Holding Corporation reported reduced net losses and increased cash, but faces substantial doubt about its ability to continue as a going concern and a Nasdaq minimum bid price non-compliance.

SeaStar Medical Holding Corporation reported a significant reduction in net loss and increased cash reserves for the first half of 2025, driven by initial commercial sales of QUELIMMUNE and reduced operating expenses, despite ongoing liquidity concerns.

SeaStar Medical Holding Corporation reports its Q1 2025 financial results, highlighting initial revenue from its pediatric Selective Cytopheretic Device (SCD) therapy and ongoing clinical trials for adult applications.

SeaStar Medical's Q3 2024 report reveals initial revenue from pediatric device sales, alongside ongoing financial losses and a need for additional capital.

SeaStar Medical's Q2 2024 results show a net loss of $3.2 million, with the company facing liquidity concerns despite FDA approval and initial commercial shipments of its pediatric SCD device.

SeaStar Medical Holding Corporation's latest 10-K filing reveals increased revenue from its pediatric SCD therapy but highlights substantial doubt about its ability to continue as a going concern due to ongoing losses and capital needs.

SeaStar Medical Holding Corporation files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted information, correct typographical errors, and file new certifications.

SeaStar Medical's 10-K filing details its 2024 financial results, commercial progress with its FDA-approved pediatric device, and ongoing clinical trials for its adult AKI therapy.

SeaStar Medical Holding Corporation provides a detailed description of its common stock, warrants, and anti-takeover provisions in an amended 10-K filing.

SeaStar Medical has filed an amendment to its annual report to correct typographical errors, include previously omitted information, and update share information.

SeaStar Medical's 2023 annual report highlights FDA approval for its pediatric device, ongoing clinical trials for adults, and significant financial losses.

SeaStar Medical Holding Corp CEO Eric Schlorff was granted 10,288 restricted stock units, with vesting scheduled over the next two years.

SeaStar Medical Holding Corp reports a restricted stock unit award granted to Chief Medical Officer Kevin Chung, with vesting scheduled over multiple dates.

SeaStar Medical Holding Corp reports a restricted stock unit award to Director Bernadette N. Vincent, with vesting scheduled for July 1, 2027.

SeaStar Medical Holding Corp reports a transaction where Director John Neuman acquired 4,000 restricted stock units.

SeaStar Medical Holding Corp reports a transaction where Director Kenneth Van Heel acquired 4,000 restricted stock units.

Director Jennifer A. Baird acquired 4,000 restricted stock units of SeaStar Medical Holding Corp. on July 1, 2026, with full vesting expected on July 1, 2027.

SeaStar Medical Holding Corporation is seeking stockholder approval for a 1-for-10 reverse stock split and a reduction in authorized common shares to maintain Nasdaq listing and support future growth.

SeaStar Medical is holding its 2025 Annual Meeting of Stockholders virtually on July 3, 2025, to vote on key proposals including director elections, equity incentive plan amendments, and a potential stock issuance to Lincoln Park Capital Fund, LLC.

SeaStar Medical Holding Corporation will hold its annual meeting of stockholders on July 3, 2025, to vote on key proposals including the election of directors, an amendment to the equity incentive plan, approval of potential stock sales to Lincoln Park Capital Fund, and ratification of the company's accounting firm.

SeaStar Medical Holding Corporation amends its proxy statement to clarify the number of outstanding shares as of January 31, 2025, before its Special Meeting of Stockholders.

SeaStar Medical Holding Corporation is holding a special meeting on March 20, 2025, to seek stockholder approval for the issuance of common warrants and the extension of the term of Series B warrants to comply with Nasdaq listing rules.

SeaStar Medical is holding a special meeting to ratify prior share issuances to maintain its Nasdaq listing and to approve a reduction in the number of authorized shares of common stock.

SeaStar Medical Holding Corporation has filed an S-1/A amendment to register up to 2,000,000 shares of common stock for resale by Lincoln Park Capital Fund, LLC.

SeaStar Medical Holding Corporation is registering for resale up to 1,664,543 shares of its Common Stock by Lincoln Park Capital Fund, LLC, with potential proceeds up to $14.7 million.

SeaStar Medical Holding Corporation is registering shares for resale by securityholders, while grappling with significant losses, Nasdaq compliance issues, and ongoing capital needs despite recent product commercialization.

SeaStar Medical Holding Corporation is offering up to 5.15 million shares of common stock and accompanying warrants to raise approximately $4.3 million in net proceeds, as the company faces substantial doubt about its ability to continue as a going concern and a Nasdaq delisting threat.

SeaStar Medical Holding Corporation has filed an S-1 registration statement to offer up to 4.2 million shares and accompanying warrants, seeking to raise capital for its medical device development and commercialization efforts while addressing ongoing Nasdaq listing compliance issues and advancing its pivotal adult AKI clinical trial.

SeaStar Medical plans to raise up to $15 million by reselling common stock through Lincoln Park Capital Fund, aiming to bolster working capital and general corporate purposes.

Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, reported beneficial ownership of 443,253 shares of SeaStar Medical Holding Corporation common stock, representing 9.99% of the outstanding shares as of March 31, 2026.

Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri have filed a Schedule 13G reporting a 6.52% beneficial ownership stake in SeaStar Medical Holding Corporation.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has reported a 9.99% beneficial ownership stake in SeaStar Medical Holding Corporation.

Armistice Capital and Steven Boyd have filed an amended Schedule 13G, disclosing a 4.99% beneficial ownership stake in SeaStar Medical Holding Corp.

Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri disclose a passive 2.6% beneficial ownership stake in SeaStar Medical Holding Corp, primarily through warrants.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has disclosed a passive beneficial ownership of 9.99% in SeaStar Medical Holding Corporation's common stock.